Developing a new product often requires substantial investments. Therefore, securing a patent provides a competitive advantage to the company with exclusive rights to exploit its invention commercially. In collaboration with a professional and award-winning law firm, Glycanostics submitted a European patent application covering its diagnostic method. The application is currently filed in two patent offices in Europe and Luxemburg.
Jan Tkac, Сo-Founder and Executive Manager of Glycanostics Ltd., comments:
“A patent always gives a sound basis for negotiating funding for development costs as well as for entering into sales and licensing agreements. In this way, patent protection provides a good opportunity for the company to secure its investments and cover product development costs in the future!”
After the patent is secured, Glycanostics can proceed with the next steps to bring its innovative PCa early diagnostic products to the market. The first product—Prostate Cancer DX Kit—is an innovative test based on analysis of molecular changes in the carbohydrate content of a prostate-specific antigen in the blood. The test offers high assay sensitivity, specificity, and accuracy of prostate cancer diagnostics. It is designed to help decide whether a confirmatory biopsy is needed. Another Glycanoctics product—Prostate Check Home Test—is designed to check the health status of the prostate comfortably at home, at an affordable price, using only one drop of blood.
On Monday, June, 21st our CEO Eva Kovacova (on the right) together with CSO Jan Tkac (on the left) had a great honour to introduce the company Glycanostics to the President of the EC Mrs. Ursula von der Leyen, our Prime Minister Mr. Eduard Heger and Vice-President of the EC Mr. Maros Sefcovic. As one out of seven selected innovative companies, we presented our highly accurate, non-invasive, and early-stage cancer diagnostics that can help save the lives of millions of people worldwide.
ESET launched a prestigious ESET Science Award for exceptional scientists
Means and methods for glycoprofiling of a protein
Glycanostics successfully finished the first phase of SME Instrument
After receiving the prestigious “Seal of Excellence” on October 23, the next submission to the Horizon 2020 Programme, won a € 50 000 grant.
This project received the highest scores for its proposal in the extremely competitive evaluation process.
Glycanostics was chosen as a finalist in the Grand Finale with five other remarkable startups.
Glycanoctics innovations are again supported and highly ranked by leading industry experts. This time the company won the European Research Council (ERC) Proof of Concept Grant.
The competition's objectives are to actively support innovative projects with high market potential
In April 2018 the technology validation was successfully completed indicating a great potential of Glycanostics innovative products for prostate cancer (PCa) diagnostics.
Glycanostics is an innovative start-up company established in 2017 to bring its revolutionary cancer diagnostics products to the US and EU markets.